CVKD · Cadrenal Therapeutics, Inc.
$0.84
-0.07 (-8.22%)
At close · Oct 12
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors, among others, raise substantial doubt about the Company's ability to continue as a going concern for at least one year from the date the accompanying financial statements are issued.”View the 10-Q filed Aug 13, 2026
Market Cap
$3.25M
Shares
3.57M
Volume · Oct 12
63.77K
Avg daily vol (3M)
453.56K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.91
Open$0.97
Day$0.90–0.97
52W close$0.91–14.19
Avg vol 30d920K
Short int106K · 3.0% float · 1.1d
Short vol63%
Last earningsAug 11, 2025
DataJan 2023–Oct 2026
Filing10-Q · Aug 13
Up next
filed Aug 13, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$11.54M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+48.5%
Year over year · more shares
Price change (1Y)
-93.6%
Trailing year
Short interest
3.0%
Latest settlement · 1.1 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 14.8 · calm
Equity put/call 0.56
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−79%
below
Price vs 50-day avg
−35%
below
RSI (14)
31
neutral
MACD trend
Positive
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−17%
trailing
6-month return
−83%
trailing
YTD return
−87%
this year
Relative strength
−93%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $4 — 200d above 50d
Institutional flow
Accumulating
3 of 19 funds reported for Sep 30 · net +1.7K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.97% of float · ▼ -10.8% MoM · 1.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
19 holders — mid 3-yr range
Squeeze score
46
elevated · 0–100
Fundamentals
EPS growth
+24%
Y/Y
Free cash flow
$-12.6M
Quant / Vol
risk profile
Volatility
100%
annualized · 1-yr
Max drawdown
−94%
past year
ATR
14.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−79%
Bearish
Price vs 50-day avg
−35%
Bearish
RSI (14)
31
Neutral
MACD trend
Positive
Bullish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $4 — 200d above 50d
Institutional flow
Accumulating
3 of 19 funds reported for Sep 30 · net +1.7K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.97% of float · ▼ -10.8% MoM · 1.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
19 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $1 · 0%
Range high $14
vs 200-day avg -79%
vs 50-day avg -35%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CVKD
this stock
Cadrenal Therapeutics, Inc.
|
$3.25M | -86.6% | — | — | 3.0% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$129.29B | +12.5% | +46.2% | 29.7 | 1.8% |
|
MRNA
Moderna, Inc.
|
$89.83B | +663.0% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$76.86B | -3.3% | +20.8% | 18.5 | 2.1% |
|
CSLLY
Csl Ltd
|
$61.83B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CVKD | -3.2% | -16.5% | -82.7% | -15.7% | -86.6% |
| SPY | +1.2% | +1.9% | +9.9% | +2.1% | +14.2% |
| vs SPY | -4.4% | -18.4% | -92.5% | -17.8% | -100.8% |